Evidence map›Paper›PMID 40657646›Full record

ReviewFrontiers in pharmacology2025

A review of natural compounds to regulate platelet aggregation: molecular mechanism and research advance.

Yi Hou, Hong Li, Luochen Zhu, Yue Li, Yue Zeng, Tian Quan, Zhangqiang Xiang, Yue Zhang, Yuan Bian, Yuxun Wei

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi HouPharmacy Department, Clinical Trial Institution, The People's Hospital of Zhongjiang, Deyang, China.
Hong LiWest China School of Medicine, Sichuan University, Chengdu, China.
Luochen ZhuDepartment of Pharmacy, Nantong Tumor Hospital (Tumor Hospital Affiliated to Nantong University), Nantong, China.
Yue LiMolecular Urooncology Department of Urology Klinikum rechts der Isar Technical University of Munich Ismaningerstr, München, Germany.
Yue ZengPharmacy Department, Clinical Trial Institution, The People's Hospital of Zhongjiang, Deyang, China.
Tian QuanPharmacy Department, Clinical Trial Institution, The People's Hospital of Zhongjiang, Deyang, China.
Zhangqiang XiangPhase 1 Clinical Trial Center, Deyang People's Hospital, Deyang, China.
Yue ZhangPharmacy Department, Clinical Trial Institution, The People's Hospital of Zhongjiang, Deyang, China.
Yuan BianDepartment of Oncology, Xichang People's Hospital, Xichang, China.
Yuxun WeiPharmacy Department, Clinical Trial Institution, The People's Hospital of Zhongjiang, Deyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelets are a class of blood cells exfoliated from bone marrow megakaryocytes and important participants in the blood. Aggregation is a prominent part of the platelets involved in the hemostasis process, regulated by multiple signaling pathways. Abnormal platelet aggregation could lead to thrombosis or hemorrhagic disorders, which is closely related to the abnormal expression of receptors inside and outside platelet cells and the mis-transmission of signaling factors. In recent years, natural compounds have been shown to regulate platelet aggregation on different levels, including platelet surface receptors, intracellular signaling factors, and release reaction from platelet secretory granules, due to their structiral characteristics. However, the anti-platelet aggregation mechanism of natural compounds is not comprehensive. Therefore, we have elaborated the main pathways that affect platelet aggregation in terms of the adenosine diphosphate (ADP), the levels of cAMP and cGMP, arachidonic acid (ARA) metabolism pathway, thrombin and collagen pathways in this paper. Particularly, we reviewed various natural compounds such as glycosides, coumarins, alkaloids, and acids that affect platelet aggregation mechanisms through these pathways. This review provides a reference for the application of natural compounds in the structural modification of platelet aggregation as well as in clinical studies.

Indexed as

clinical trialsmolecular mechanismnatural compoundsplatelet activationplatelet aggregation

Identifiers

PMID40657646
PMCPMC12245885

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.